The ecological approach to biologic drugs: survival of the fittest

2021 ◽  
Author(s):  
R. Gniadecki
Keyword(s):  
Ecological Approach ◽  
Biologic Drugs ◽  
Survival Of The Fittest

Collective Human Agency in the Context of Organizational Participation

2017 ◽  
Vol 61 (2) ◽  
pp. 51-68 ◽  
Author(s):  
Wolfgang Georg Weber ◽  
Hans Jeppe Jeppesen
Keyword(s):  
Collective Efficacy ◽  
Social Cognitive ◽  
Work Motivation ◽  
Human Agency ◽  
Employee Participation ◽  
Ecological Approach ◽  
Cognitive Approach ◽  
Organizational Decision Making ◽  
Organizational Participation ◽  
The Social

Abstract. Connecting the social cognitive approach of human agency by Bandura (1997) and activity theory by Leontiev (1978) , this paper proposes a new theoretical framework for analyzing and understanding employee participation in organizational decision-making. Focusing on the social cognitive concepts of self-reactiveness, self-reflectiveness, intentionality, and forethought, commonalities, complementarities, and differences between both theories are explained. Efficacy in agency is conceived as a cognitive foundation of work motivation, whereas the mediation of societal requirements and resources through practical activity is conceptualized as an ecological approach to motivation. Additionally, we discuss to which degree collective objectifications can be understood as material indicators of employees’ collective efficacy. By way of example, we explore whether an integrated application of concepts from both theories promotes a clearer understanding of mechanisms connected to the practice of employee participation.

APA Multicultural Guidelines executive summary: Ecological approach to context, identity, and intersectionality.

2019 ◽  
Vol 74 (2) ◽  
pp. 232-244 ◽  
Author(s):  
Caroline S. Clauss-Ehlers ◽  
David A. Chiriboga ◽  
Scott J. Hunter ◽  
Gargi Roysircar ◽  
Pratyusha Tummala-Narra
Keyword(s):  
Ecological Approach ◽  
Executive Summary

The Evolutionary Dynamics of Decision Rule Selection

2017 ◽  
Author(s):  
Michael Laver ◽  
Ernest Sergenti
Keyword(s):  
Decision Rule ◽  
Positive Feedback ◽  
Party System ◽  
Evolutionary Dynamics ◽  
Decision Rules ◽  
Past Performance ◽  
Party Leaders ◽  
Track Record ◽  
Long Run ◽  
Survival Of The Fittest

This chapter extends the survival-of-the-fittest evolutionary environment to consider the possibility that new political parties, when they first come into existence, do not pick decision rules at random but instead choose rules that have a track record of past success. This is done by adding replicator-mutator dynamics to the model, according to which the probability that each rule is selected by a new party is an evolving but noisy function of that rule's past performance. Estimating characteristic outputs when this type of positive feedback enters the dynamic model creates new methodological challenges. The simulation results show that it is very rare for one decision rule to drive out all others over the long run. While the diversity of decision rules used by party leaders is drastically reduced with such positive feedback in the party system, and while some particular decision rule is typically prominent over a certain period of time, party systems in which party leaders use different decision rules are sustained over substantial periods.

Pharmacoeconomic analysis of using genetically engineered biologic drugs for treating adult patients with moderate to severe plaque psoriasis in the Russian Federation

2020 ◽  
pp. 57-65
Author(s):  
Maksim Frolov ◽  
Vladimir Rogov ◽  
Alla Salasyuk
Keyword(s):  
Plaque Psoriasis ◽  
Impact Analysis ◽  
Pharmacoeconomic Analysis ◽  
Certolizumab Pegol ◽  
Genetically Engineered ◽  
Adult Patients ◽  
Comparable Efficacy ◽  
Biologic Drugs ◽  
Severe Plaque Psoriasis ◽  
Cost Minimisation Analysis

The aim of the study was to assess clinical and economic effectiveness of netakimab compared to other genetically engineered biologic drugs (infliximab, adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab, certolizumab pegol) for the treatment of adult patients with moderate to severe plaque psoriasis. We have conducted cost-benefit analysis, cost-minimisation analysis, and budget impact analysis. We have considered only direct medical costs. The results of the study show that netakimab has higher or comparable efficacy and significantly lower costs compared to other biologic drugs, that makes it the most preferable treatment option for patients with moderate to severe plaque psoriasis. Use of netakimab in clinical practice will significantly reduce budget expenditures and increase patient access to biologic therapy.

Biologic Drugs for Analgesia: Redefining the Opportunity

2011 ◽  
Vol 12 (10) ◽  
pp. 1660-1670 ◽  
Author(s):  
Jane Hughes ◽  
Jonathan P. Hatcher ◽  
Iain P. Chessell
Keyword(s):  
Biologic Drugs
Sign in / Sign up

Export Citation Format

Share Document